Omega Funds
Investor profile
Venture capital
Also recorded as: Omega · Omega Venture Partners
Deals
11
distinct rounds
Companies
9
backed
Active span
2020–2025
6 yrs
Total round €
€536M
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- Andera Partners2
- Avidity Partners2
- Brandon Capital2
- Invus2
- M Ventures2
- Novartis Venture Fund2
- Pfizer Ventures2
- Piper Heartland Healthcare Capital2
- Schroders Capital2
- Sofinnova Partners2
- SV Health Investors2
- Abingworth LLP1
- Bain Capital Life Sciences1
- British Business Bank1
- CaaS Capital Management1
- Criteria Bio Ventures1
- Deep Track Capital1
- EQT Life Sciences1
- European Investment Bank (EIB)1
- Frumtak Ventures1
- FundPlus1
- GIMV1
- Grand Pharma1
- IP Group PLC1
- Janus Henderson Investors1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Artios | UK | 2 | €229M |
| NRG Therapeutics | UK | 2 | €76M |
| EyeBiotech | UK | 1 | €60M |
| SoniVie | Italy | 1 | €55M |
| Anjarium Biosciences | Switzerland | 1 | €51M |
| eTheRNA | Belgium | 1 | €39M |
| Chord Therapeutics | Switzerland | 1 | €14M |
| Treble Technologies | Iceland | 1 | €11M |
| Evolytes | Iceland | 1 | €1.3M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Artios | Series C | €129M | 2021-07 |
| Artios | Series D+ | €99M | 2025-11 |
| EyeBiotech | Series A | €60M | 2023-11 |
| NRG Therapeutics | Series B | €58M | 2025-09 |
| SoniVie | Series C | €55M | 2023-01 |
| Anjarium Biosciences | Series A | €51M | 2021-09 |
| eTheRNA | Series B | €39M | 2022-08 |
| NRG Therapeutics | Series A | €18M | 2022-11 |
| Chord Therapeutics | Series A | €14M | 2020-10 |
| Treble Technologies | Series A | €11M | 2024-09 |